Doximity Inc DOCS stock is trading higher on Friday after the company reported third-quarter fiscal 2025 results that beat analysts’ expectations and upbeat guidance.Doximity reported adjusted EPS of 45 cents, up from 29 cents a year ago and beating the consensus of 34 cents.Sales increased 25% year-over-year to $168.6 million, beating the consensus of $152.82 million and management guidance of $152 million to $153 million.Doximity offers a digital platform for U.S. medical professionals“We’re proud to deli ...

According to data provided by S&P Global Market Intelligence, the "Bloomberg platform for medical professionals," Doximity (DOCS 34.88%), saw its shares spike 34% as of 11:20 a.m. ET Friday.The healthcare upstart rocketed past analysts' expectations on both the top and bottom lines and guided for a rosier upcoming quarter than anticipated.However, a few nuggets hidden in Doximity's earnings call may be the real reason for the market's exuberant reaction today.Doximity's investment thesis looks better than e ...

For its fiscal fourth quarter, Doximity said it expects to report revenue between $132.5 million and $133.5 million, while analysts were expecting $123.8 million. The company also raised guidance for its full fiscal year and expects to report revenue between $564.6 million and $565.6 million.The company built a digital platform for medical professionals that helps carry out telehealth appointments with patients, find referrals, stay current on medical news and more. Doximity's revenue increased 25% to $168. ...

Financial Data and Key Metrics Changes - The company reported $169 million in revenue for Q3 FY2025, representing a 25% year-on-year growth and a 10% beat from the high end of guidance [10] - Adjusted EBITDA margin reached a record 61%, or $102 million, which was up 39% year-on-year and 21% above the high end of guidance [11][22] - Free cash flow for Q3 was $63.4 million, an increase of 30% year-over-year [24] Business Line Data and Key Metrics Changes - The top twenty clients grew by 122% on a trailing twelve-month basis, indicating strong demand from major pharmaceutical companies [10] - Unique active users across various engagement metrics hit fresh highs, with over 610,000 unique active prescribers using workflow tools [12][13] - New point of care and formulary products grew over 100% in Q3, contributing over 20% of pharmaceutical sales [15] Market Data and Key Metrics Changes - The company finished the quarter with a net revenue retention rate of 117% on a trailing twelve-month basis, with top twenty customers at 122% [21] - The digital market for pharma healthcare professionals is expected to grow at a rate of 5 to 7% [34] Company Strategy and Development Direction - The company is focusing on expanding its client portal, with plans to onboard all clients by 2025 [18] - Integrated programs are being emphasized, allowing clients to personalize and optimize their campaigns, which has led to larger deal sizes [17][27] - The company aims to grow ahead of the overall market, leveraging strong competitive positioning and record engagement [34] Management's Comments on Operating Environment and Future Outlook - Management noted that the majority of growth was driven by share gains rather than overall market improvement, outperforming the market by about 3x this year [108] - The company expects to see a more consistent revenue curve as more customers move into multi-module integrated programs [61] - There is optimism about the potential for growth in the pharma digital market, as it remains under-indexed compared to other industries [145][146] Other Important Information - The company repurchased $19.2 million worth of shares during Q3, with $451 million remaining in the repurchase program [24] - AI tools are being utilized to enhance operational efficiency, contributing to margin expansion [88][89] Q&A Session Summary Question: Insights on customer buying patterns between portal users and non-portal users - Management indicated that portal clients have shown higher growth and that the portal allows for better tracking of return on investment [38] Question: Clarification on EBITDA margins - Management explained that the high EBITDA margin in Q3 was due to top-line outperformance and that quarterly variations should be expected [42] Question: Drivers of momentum in sales - Management attributed the momentum to both new products and the rollout of the client portal, which facilitates easier transactions [48] Question: Changes in revenue recognition seasonality - Management noted that larger multi-module integrated programs could lead to a more consistent revenue curve year-over-year [61] Question: Targeting nurse practitioners and physician assistants - The company has over 60% of nurse practitioners as members and is focused on expanding this segment [64] Question: Revenue from point of care and formulary products - Management stated that point of care products account for 20% of overall revenue and see significant growth potential in AI products [140] Question: Future product roadmap - Management expressed excitement about new product ideas, particularly in AI, which has not yet been monetized [87] Question: Market growth expectations - Management believes that the 5 to 7% growth rate for the pharma digital market could increase as the industry shifts more budget towards digital [146]

Doximity (DOCS) Q3 2025 Earnings Call February 07, 2025 02:14 AM ET Company Participants Perry Gold - VP-IRJeff Tangney - Co-Founder and CEOAnna Bryson - CFOBrian Peterson - Managing DirectorGlen Santangelo - Managing DirectorRyan Daniels - Group Head–Healthcare Technology and ServicesRichard Close - Managing DirectorScott Schoenhaus - Managing DirectorNate Gross - Co-Founder & Chief Strategy OfficerAnne Samuel - Executive DirectorJeff Garro - Managing DirectorDavid Roman - Managing DirectorJailendra Singh ...

INVESTOR PRESENTATION Winter 2025 LEGAL DISCLAIMER This presentation and associated commentary may contain forward-looking statements, including statements regarding expectations of future results of operations or financial performance of Doximity, market size and growth opportunities, the calculation of certain of our key financial and operating metrics, capital expenditures, plans for future operations, competitive position, technological capabilities, and strategic relationships, general business conditi ...

Company Performance - Doximity reported quarterly earnings of $0.45 per share, exceeding the Zacks Consensus Estimate of $0.33 per share, and up from $0.29 per share a year ago, representing an earnings surprise of 36.36% [1] - The company posted revenues of $168.6 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 10.60%, compared to $135.28 million in the same quarter last year [2] - Doximity has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Stock Performance - Doximity shares have increased approximately 8.9% since the beginning of the year, outperforming the S&P 500's gain of 3.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.22 on revenues of $123.88 million, and for the current fiscal year, it is $1.14 on revenues of $539.15 million [7] - The estimate revisions trend for Doximity is mixed, and future earnings expectations will be influenced by management's commentary during the earnings call [3][4] Industry Context - The Medical Services industry, to which Doximity belongs, is currently ranked in the bottom 34% of over 250 Zacks industries, which may impact stock performance [8] - Another company in the same industry, NeueHealth, is expected to report a quarterly loss of $2.29 per share, indicating challenges within the sector [9]

Doximity at the New York Stock Exchange for their IPO, June 24, 2021.Shares of Doximity popped 21% on Thursday after the company reported third-quarter fiscal 2025 results that beat analysts' expectations for revenue and offered rosy guidance.Here's how the company did:Earnings per share: 37 cents. That may not compare with the 34 cents expected by LSEG.Revenue: $168.6 million vs. $152.8 million expected by LSEG.Doximity is a digital platform for medical professionals that helps clinicians stay current on m ...

Doximity exceeded expectations with strong revenue and net income growth, highlighting robust operational performance.Doximity (DOCS), a digital platform for U.S. medical professionals, released its fiscal third-quarter earnings on Feb. 6, 2025. The company reported impressive results, surpassing both analyst forecasts and its own guidance. It achieved a non-GAAP earnings per share (EPS) of $0.45, well above the estimate of $0.34. Revenue reached $168.6 million, compared to expectations of $152 million. Ove ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q _________________________________________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 500 3rd St. OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Suite 510 For the transition period from to ...